<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236090</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-VIV-2016-109</org_study_id>
    <nct_id>NCT03236090</nct_id>
  </id_info>
  <brief_title>Effect of Vivomixx® on Neuroinflammation in Patients Withs Cirrhosis</brief_title>
  <official_title>Study of the Effect of Vivomixx® on Neuroinflammation Ans Systemic Inflammatory Response in Patients With Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Clinical Research Network - SCReN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design:&#xD;
&#xD;
      Double-blind randomized placebo-controlled clinical trial&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      2 years&#xD;
&#xD;
      Study Center:&#xD;
&#xD;
      Single center Hospital de la Santa Creu i Sant Pau, Barcelona&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To assess the effect of Vivomixx® on neuroinflammation and systemic inflammatory response in&#xD;
      patients with cirrhosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study variables Main variables&#xD;
&#xD;
        -  Neuroinflammation&#xD;
&#xD;
        -  Systemic inflammatory response Secondary variables&#xD;
&#xD;
        -  Cognitive function&#xD;
&#xD;
        -  Bacterial translocation&#xD;
&#xD;
        -  Intestinal barrier&#xD;
&#xD;
        -  Systemic oxidative damage&#xD;
&#xD;
        -  Time until SBP or other bacterial infection resolution in patients with infections&#xD;
&#xD;
        -  Incidence of complications of cirrhosis and mortality during the study 40 patients, 20&#xD;
           and 30 in each of the two substudies, respectively Diagnosis and Main Inclusion Criteria&#xD;
&#xD;
        -  Decompensated patients with cirrhosis:&#xD;
&#xD;
             1. Outpatients with refractory ascites (substudy 1) (n=20)&#xD;
&#xD;
             2. Patients hospitalized because bacterial infection (substudy 2) (n=30)&#xD;
&#xD;
      Study Product:&#xD;
&#xD;
      Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)&#xD;
&#xD;
      Duration of administration:&#xD;
&#xD;
      30 days Follow up The following patients' assessments will be performed: in substudy 1 at&#xD;
      baseline and at the end of the treatment (30 days), and in substudy 2 at baseline, on day 1,&#xD;
      day 2, day 3, day 7, at infection resolution, and at discharge or day 30.&#xD;
&#xD;
      Clinical and analytical assessments will be performed every three months after the end of the&#xD;
      study Comparator Placebo (we evaluate the probiotic Vivomixx® vs placebo as adjunctive in&#xD;
      addition to the standard of care) Statistical Methodology Fisher's exact test for categorical&#xD;
      variables and Student's &quot;t&quot; test and Mann-Whitney and Wilcoxon tests for quantitative&#xD;
      variables. Correlations will be assessed by Spearman test. A two-sided p value &lt;0.05 will be&#xD;
      considered statistically significant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Problems to recruit patients due to exclusion criteria&#xD;
  </why_stopped>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Actual">March 9, 2018</completion_date>
  <primary_completion_date type="Actual">March 9, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Decompensated patients with cirrhosis:&#xD;
Outpatients with refractory ascites (substudy 1) (n=20)&#xD;
Patients hospitalized because bacterial infection (substudy 2) (n=30)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Placebo (we evaluate the probiotic Vivomixx® vs placebo as adjunctive in addition to the standard of care)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neuroinflammation</measure>
    <time_frame>Change from baseline at 30 days</time_frame>
    <description>For substudy 1, neuroinflammation will be measured by MRI at baseline and 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in neuroinflammation</measure>
    <time_frame>Change from baseline at 3 days</time_frame>
    <description>For substudy 2, neuroinflammation will be measured by MRI at baseline and 3 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Outpatients with refractory ascites</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients hospitalized because bacterial infection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vivomixx</intervention_name>
    <description>Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)</description>
    <arm_group_label>Outpatients with refractory ascites</arm_group_label>
    <arm_group_label>Patients hospitalized because bacterial infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients with cirrhosis and refractory ascites according to current definition (29)&#xD;
             (substudy 1), and hospitalized patients with cirrhosis and an episode of bacterial&#xD;
             infection (substudy 2) at Hospital de la Santa Creu i Sant Pau.&#xD;
&#xD;
        Cirrhosis will be diagnosed by clinical, analytical and ultrasonographic findings or by&#xD;
        liver biopsy. SBP will be diagnosed by an ascitic fluid neutrophil count &gt; 250/mm3 with or&#xD;
        without positive culture (28). Bacteremia, urinary infections, pneumonia, cellulitis, other&#xD;
        bacterial infections and possible or suspected infections will be diagnosed according to&#xD;
        current guidelines (13,14,28). All patients with SBP, bacteremia or pneumonia will be&#xD;
        included. However patients with urinary infections, cellulitis or suspected infection these&#xD;
        non-SBP infections will be required to fulfil the following requirements: at least two&#xD;
        criteria of SIRS (systemic inflammatory response syndrome) (Annex I) (30) and CRP&#xD;
        (C-reactive protein) &gt;= 10 mg/dl (28).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced hepatocellular carcinoma (beyond Milan's criteria) or any other malignancy&#xD;
             determining a poor short-term prognosis.&#xD;
&#xD;
          -  Advanced liver insufficiency [MELD (model for end-stage liver disease) &gt;25].&#xD;
&#xD;
          -  Marked symptomatic comorbidities (neurological, cardiac, pulmonary, renal,&#xD;
             psychiatric, HIV infection).&#xD;
&#xD;
          -  Septic shock, ileus, need for tracheal intubation or intensive care unit.&#xD;
&#xD;
          -  Immunomodulatory drugs.&#xD;
&#xD;
          -  In substudy 1, any infection at inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Systemic inflammation</keyword>
  <keyword>neuroinflammation</keyword>
  <keyword>Cognitive function</keyword>
  <keyword>Bacterial translocation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

